ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER

Clinical trials for ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER explained in plain language.

Never miss a new study

Get alerted when new ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER trials appear

Sign up with your email to follow new studies for ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Experimental drug offers hope for patients Who've run out of options

Disease control Recruiting now

This study is testing a new immunotherapy drug called BI 3820768 for the first time in people. It's for adults with advanced germ cell, endometrial, or ovarian cancer that has returned or stopped responding to standard treatments. The main goal is to find a safe and tolerable dos…

Matched conditions: ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER

Get alerted when new ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER trials appear

Experimental drug offers hope for patients Who've run out of options